📊 MRNA Key Takeaways
Is MRNA a Good Investment? Thesis Analysis
Moderna is experiencing severe operational distress with negative net income of $2.8B, collapsing revenue (-39.9% YoY), and negative free cash flow of $2.1B, indicating the company cannot sustain current operations without burning cash reserves. While the balance sheet provides a liquidity cushion with $2.6B in cash and a healthy 3.29x current ratio, the deteriorating fundamentals suggest fundamental business challenges requiring urgent strategic repositioning.
Why Buy MRNA? Key Strengths
- Strong liquidity position with $2.6B cash and 3.29x current ratio provides 12+ months operating runway
- Manageable leverage with 0.07x debt-to-equity ratio limits financial distress risk in near-term
- Net loss improved 20.8% YoY despite revenue collapse, suggesting some cost control efforts
MRNA Investment Risks to Consider
- Operating losses of $3.1B with negative 158.1% operating margin indicate core business is unprofitable and unsustainable
- Revenue declined 39.9% YoY suggesting loss of market demand, potentially from COVID vaccine revenue normalization
- Negative free cash flow of $2.1B with -106.2% FCF margin means company is rapidly depleting cash reserves and cannot self-fund operations
- Negative ROE (-32.6%) and ROA (-22.9%) demonstrate value destruction for shareholders
Key Metrics to Watch
- Quarterly revenue trends and vaccine/pipeline revenue mix to assess market recovery
- Monthly cash burn rate to determine cash runway adequacy
- Operating expense reduction progress as path to profitability
- Pipeline advancement and clinical trial results for non-vaccine candidates
MRNA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.29x current ratio provides a solid financial cushion.
MRNA Profitability Ratios
MRNA vs Healthcare Sector
How Moderna, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MRNA Overvalued or Undervalued?
Based on fundamental analysis, Moderna, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MRNA Balance Sheet & Liquidity
MRNA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Moderna, Inc.'s revenue has grown significantly by 11,274% over the 5-year period, indicating strong business expansion. The most recent EPS of $-12.33 indicates the company is currently unprofitable.
MRNA Growth Metrics (YoY)
MRNA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.0B | $13.0M | $0.03 |
| Q2 2025 | $142.0M | -$825.0M | $-2.13 |
| Q1 2025 | $108.0M | -$971.0M | $-2.52 |
| Q3 2024 | $1.8B | $13.0M | $0.03 |
| Q2 2024 | $241.0M | -$1.3B | $-3.33 |
| Q1 2024 | $167.0M | $79.0M | $0.19 |
| Q3 2023 | $1.8B | $1.0B | $2.53 |
| Q3 2019 | $17.0M | -$80.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MRNA Capital Allocation
MRNA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Moderna, Inc. (CIK: 0001682852)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRNA
What is the AI rating for MRNA?
Moderna, Inc. (MRNA) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRNA's key strengths?
Claude: Strong liquidity position with $2.6B cash and 3.29x current ratio provides 12+ months operating runway. Manageable leverage with 0.07x debt-to-equity ratio limits financial distress risk in near-term.
What are the risks of investing in MRNA?
Claude: Operating losses of $3.1B with negative 158.1% operating margin indicate core business is unprofitable and unsustainable. Revenue declined 39.9% YoY suggesting loss of market demand, potentially from COVID vaccine revenue normalization.
What is MRNA's revenue and growth?
Moderna, Inc. reported revenue of $1.9B.
Does MRNA pay dividends?
Moderna, Inc. does not currently pay dividends.
Where can I find MRNA SEC filings?
Official SEC filings for Moderna, Inc. (CIK: 0001682852) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRNA's EPS?
Moderna, Inc. has a diluted EPS of $-7.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRNA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Moderna, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRNA stock overvalued or undervalued?
Valuation metrics for MRNA: ROE of -32.6% (sector avg: 15%), net margin of -145.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MRNA stock in 2026?
Our dual AI analysis gives Moderna, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRNA's free cash flow?
Moderna, Inc.'s operating cash flow is $-1.9B, with capital expenditures of $192.0M. FCF margin is -106.2%.
How does MRNA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -145.2% (avg: 12%), ROE -32.6% (avg: 15%), current ratio 3.29 (avg: 2).